Alivus Life Sciences Share Price
1436.90+0.00 (-0.90%)
+58.98% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
ALIVUSNSE
Alivus Life Sciences Share Price
1436.90+0.00 (-0.90%)
+58.98% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | 6% | 6% | 7% |
| - | 10% | 7% | 16% |
| - | 18% | 32% | 59% |
| 83% | 22% | 19% | 18% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
ALIVUS
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,908.7 | ₹456593 Cr | 41.64 | 8.29 | 58.23 | ₹11479 Cr |
| 11,120.5 | ₹296741 Cr | 88.24 | 42.53 | 146.01 | ₹2568 Cr |
| 4,626.2 | ₹175578 Cr | 82.66 | 14.04 | 106.21 | ₹2163 Cr |
| 2,304.4 | ₹124380 Cr | 92.83 | 8.17 | 33.94 | ₹889 Cr |
| 1,235 | ₹119700 Cr | 28.64 | 9.27 | 62.23 | ₹5040 Cr |
| 1,396.5 | ₹116771 Cr | 41.71 | 11.08 | 59.16 | ₹4196 Cr |
| 1,421.8 | ₹114397 Cr | 39.49 | 10.86 | 52.6 | ₹3879 Cr |
| 2,636.7 | ₹108641 Cr | 48.44 | 17.23 | 76.25 | ₹1913 Cr |
| 1,803.3 | ₹103971 Cr | 26.06 | 19.57 | 103.44 | ₹3505 Cr |
| 2,002.6 | ₹91413 Cr | 17.56 | 25.26 | 150.99 | ₹5333 Cr |
| 1,438.5 | ₹17828 Cr | 26.62 | 16.03 | 61.16 | ₹564 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹682 Cr | ₹640 Cr | ₹689 Cr | ₹673 Cr | ₹588 Cr | ₹602 Cr | ₹650 Cr | ₹642 Cr | ₹507 Cr | ₹589 Cr | ₹537 Cr | ₹573 Cr | ₹595 Cr | ₹578 Cr | ₹621 Cr | ₹541 Cr | ₹509 Cr | ₹490 Cr | ₹514 Cr | ₹522 Cr | ₹562 Cr | ₹525 Cr | ₹467 Cr | ₹500 Cr | ₹521 Cr | ₹397 Cr |
| ₹20 Cr | ₹22 Cr | ₹23 Cr | ₹14 Cr | ₹15 Cr | ₹9 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹5 Cr | ₹3 Cr | ₹2 Cr | ₹5 Cr | ₹2 Cr | ₹3 Cr | ₹7 Cr | ₹10 Cr | ₹9 Cr | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹4 Cr | ₹34 L | ₹37 L | ₹1 L | ₹2 Cr |
| ₹702 Cr | ₹663 Cr | ₹712 Cr | ₹687 Cr | ₹603 Cr | ₹611 Cr | ₹660 Cr | ₹652 Cr | ₹515 Cr | ₹594 Cr | ₹540 Cr | ₹574 Cr | ₹601 Cr | ₹580 Cr | ₹624 Cr | ₹547 Cr | ₹519 Cr | ₹499 Cr | ₹519 Cr | ₹526 Cr | ₹564 Cr | ₹529 Cr | ₹468 Cr | ₹501 Cr | ₹521 Cr | ₹399 Cr |
| ₹439 Cr | ₹449 Cr | ₹495 Cr | ₹461 Cr | ₹427 Cr | ₹447 Cr | ₹467 Cr | ₹467 Cr | ₹388 Cr | ₹444 Cr | ₹410 Cr | ₹413 Cr | ₹441 Cr | ₹398 Cr | ₹426 Cr | ₹406 Cr | ₹376 Cr | ₹353 Cr | ₹381 Cr | ₹386 Cr | ₹404 Cr | ₹373 Cr | ₹306 Cr | ₹354 Cr | ₹402 Cr | ₹267 Cr |
| ₹285 Cr | ₹234 Cr | ₹237 Cr | ₹245 Cr | ₹194 Cr | ₹181 Cr | ₹209 Cr | ₹201 Cr | ₹143 Cr | ₹165 Cr | ₹145 Cr | ₹174 Cr | ₹172 Cr | ₹195 Cr | ₹209 Cr | ₹152 Cr | ₹154 Cr | ₹156 Cr | ₹147 Cr | ₹150 Cr | ₹169 Cr | ₹164 Cr | ₹170 Cr | ₹155 Cr | ₹127 Cr | ₹140 Cr |
| ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹46 L | ₹34 L | ₹35 L | ₹36 L | ₹39 L | ₹40 L | ₹40 L | ₹12 L | ₹16 L | ₹13 L | ₹14 L | ₹13 L | ₹6 L | ₹7 Cr | ₹21 Cr | ₹21 Cr | ₹22 Cr | ₹22 Cr | ₹23 Cr |
| ₹262 Cr | ₹212 Cr | ₹216 Cr | ₹198 Cr | ₹174 Cr | ₹163 Cr | ₹191 Cr | ₹185 Cr | ₹127 Cr | ₹150 Cr | ₹130 Cr | ₹161 Cr | ₹159 Cr | ₹182 Cr | ₹198 Cr | ₹141 Cr | ₹144 Cr | ₹146 Cr | ₹138 Cr | ₹140 Cr | ₹153 Cr | ₹135 Cr | ₹141 Cr | ₹125 Cr | ₹97 Cr | ₹108 Cr |
| ₹197 Cr | ₹160 Cr | ₹163 Cr | ₹150 Cr | ₹130 Cr | ₹122 Cr | ₹142 Cr | ₹137 Cr | ₹95 Cr | ₹111 Cr | ₹98 Cr | ₹119 Cr | ₹119 Cr | ₹135 Cr | ₹146 Cr | ₹105 Cr | ₹107 Cr | ₹109 Cr | ₹99 Cr | ₹104 Cr | ₹115 Cr | ₹101 Cr | ₹105 Cr | ₹93 Cr | ₹72 Cr | ₹81 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — |
| ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 L |
| ₹7 Cr | ₹10 Cr | ₹11 Cr | ₹7 Cr | ₹3 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹3300 Cr | ₹2783 Cr | ₹2297 Cr | ₹2107 Cr | ₹2026 Cr | ₹751 Cr | ₹400 Cr | ₹86 Cr | -₹1 Cr |
| ₹3300 Cr | ₹2783 Cr | ₹2297 Cr | ₹2107 Cr | ₹2026 Cr | ₹751 Cr | ₹400 Cr | ₹86 Cr | -₹1 Cr |
| ₹3332 Cr | ₹2817 Cr | ₹2332 Cr | ₹2138 Cr | ₹2054 Cr | ₹753 Cr | ₹402 Cr | ₹88 Cr | -₹1 Cr |
| ₹58 Cr | ₹54 Cr | ₹49 Cr | ₹42 Cr | ₹31 Cr | ₹23 Cr | ₹16 Cr | ₹7 Cr | ₹0 |
| ₹49 Cr | ₹51 Cr | ₹15 Cr | ₹17 Cr | ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹36 Cr | ₹361 Cr | ₹693 Cr | ₹8 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹143 Cr | ₹466 Cr | ₹757 Cr | ₹67 Cr | ₹33 Cr | ₹23 Cr | ₹16 Cr | ₹7 Cr | ₹0 |
| — | — | — | — | — | — | — | — | — |
| ₹372 Cr | ₹390 Cr | ₹369 Cr | ₹427 Cr | ₹308 Cr | ₹221 Cr | ₹201 Cr | ₹183 Cr | ₹1 L |
| ₹99 Cr | ₹63 Cr | ₹58 Cr | ₹55 Cr | ₹50 Cr | ₹967 Cr | ₹1084 Cr | ₹1181 Cr | ₹1 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹2 L | ₹2 L | ₹0 |
| ₹211 Cr | ₹17 Cr | ₹12 Cr | ₹533 Cr | ₹389 Cr | ₹257 Cr | ₹22 Cr | ₹16 Cr | ₹1 L |
| ₹682 Cr | ₹470 Cr | ₹439 Cr | ₹1015 Cr | ₹747 Cr | ₹1445 Cr | ₹1307 Cr | ₹1380 Cr | ₹1 Cr |
| ₹4157 Cr | ₹3754 Cr | ₹3528 Cr | ₹3220 Cr | ₹2834 Cr | ₹2221 Cr | ₹1726 Cr | ₹1475 Cr | ₹9 L |
| ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹2 L | ₹2 L | ₹0 |
| — | — | — | — | — | — | — | — | — |
| ₹1367 Cr | ₹1219 Cr | ₹1012 Cr | ₹936 Cr | ₹706 Cr | ₹652 Cr | ₹595 Cr | ₹476 Cr | ₹10,000 |
| ₹329 Cr | ₹264 Cr | ₹207 Cr | ₹156 Cr | ₹116 Cr | ₹79 Cr | ₹49 Cr | ₹19 Cr | ₹0 |
| ₹1038 Cr | ₹955 Cr | ₹805 Cr | ₹781 Cr | ₹590 Cr | ₹573 Cr | ₹546 Cr | ₹456 Cr | ₹10,000 |
| ₹273 Cr | ₹94 Cr | ₹101 Cr | ₹49 Cr | ₹92 Cr | ₹14 Cr | ₹11 Cr | ₹80 Cr | ₹0 |
| ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹0 |
| ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹0 |
| ₹12 Cr | ₹361 Cr | ₹701 Cr | ₹9 Cr | ₹20 Cr | ₹11 Cr | ₹8 Cr | ₹8 Cr | ₹0 |
| ₹1334 Cr | ₹1418 Cr | ₹1612 Cr | ₹852 Cr | ₹706 Cr | ₹598 Cr | ₹565 Cr | ₹545 Cr | ₹10,000 |
| — | — | — | — | — | — | — | — | — |
| ₹780 Cr | ₹478 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹692 Cr | ₹674 Cr | ₹667 Cr | ₹604 Cr | ₹516 Cr | ₹513 Cr | ₹413 Cr | ₹401 Cr | ₹4 L |
| ₹1073 Cr | ₹970 Cr | ₹765 Cr | ₹807 Cr | ₹673 Cr | ₹620 Cr | ₹639 Cr | ₹448 Cr | ₹3 L |
| ₹2 Cr | ₹71 Cr | ₹302 Cr | ₹309 Cr | ₹512 Cr | ₹116 Cr | ₹10 Cr | ₹2 Cr | ₹70,000 |
| ₹39 Cr | ₹42 Cr | ₹92 Cr | ₹72 Cr | ₹6 Cr | ₹26 Cr | ₹21 Cr | ₹6 Cr | ₹0 |
| ₹237 Cr | ₹100 Cr | ₹91 Cr | ₹577 Cr | ₹420 Cr | ₹348 Cr | ₹78 Cr | ₹74 Cr | ₹80,000 |
| ₹2824 Cr | ₹2335 Cr | ₹1916 Cr | ₹2369 Cr | ₹2127 Cr | ₹1623 Cr | ₹1160 Cr | ₹931 Cr | ₹8 L |
| ₹2141 Cr | ₹1865 Cr | ₹1477 Cr | ₹1354 Cr | ₹1381 Cr | ₹178 Cr | -₹147 Cr | -₹450 Cr | -₹1 Cr |
| ₹4157 Cr | ₹3754 Cr | ₹3528 Cr | ₹3220 Cr | ₹2834 Cr | ₹2221 Cr | ₹1726 Cr | ₹1475 Cr | ₹9 L |
| ₹271 | ₹229 | ₹189 | ₹174 | ₹167 | ₹768 | ₹2,049 | ₹450 | -₹1,398 |
| ₹271 | ₹229 | ₹189 | ₹174 | ₹167 | ₹70 | ₹37 | ₹8 | -₹25 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|
| ₹751 Cr | ₹654 Cr | ₹631 Cr | ₹629 Cr | ₹565 Cr | ₹471 Cr | ₹421 Cr | ₹228 Cr | -₹1 L |
| ₹116 Cr | ₹81 Cr | ₹79 Cr | ₹45 Cr | ₹71 Cr | ₹133 Cr | ₹57 Cr | -₹101 Cr | ₹0 |
| -₹129 Cr | -₹180 Cr | -₹134 Cr | -₹214 Cr | ₹100 Cr | -₹108 Cr | -₹190 Cr | -₹93 Cr | -₹47 L |
| ₹739 Cr | ₹554 Cr | ₹576 Cr | ₹460 Cr | ₹736 Cr | ₹497 Cr | ₹288 Cr | ₹34 Cr | -₹48 L |
| ₹565 Cr | ₹392 Cr | ₹414 Cr | ₹306 Cr | ₹598 Cr | ₹388 Cr | ₹195 Cr | ₹10 Cr | -₹48 L |
| -₹570 Cr | -₹616 Cr | -₹116 Cr | -₹147 Cr | -₹122 Cr | -₹69 Cr | -₹51 Cr | -₹9 Cr | ₹0 |
| -₹64 Cr | -₹6 Cr | -₹279 Cr | -₹388 Cr | -₹79 Cr | -₹214 Cr | -₹137 Cr | ₹54 L | ₹49 L |
| -₹69 Cr | -₹230 Cr | ₹18 Cr | -₹228 Cr | ₹397 Cr | ₹106 Cr | ₹8 Cr | ₹2 Cr | ₹50,000 |
| ₹71 Cr | ₹301 Cr | ₹284 Cr | ₹512 Cr | ₹116 Cr | ₹10 Cr | ₹2 Cr | ₹70,000 | ₹20,000 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹8 L | ₹0 |
| ₹2 Cr | ₹71 Cr | ₹301 Cr | ₹284 Cr | ₹512 Cr | ₹116 Cr | ₹10 Cr | ₹2 Cr | ₹70,000 |
Fundamental Ratios
Consolidated
Standalone

No results found
Alivus Life Sciences Share Price
1436.90+0.00 (-0.90%)
+58.98% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 4 out of 9 oscillators
RSI
52.27Neutral
STOCH %K
19.64Buy
MACD Level(12,26)
22.28Buy
Ultimate Oscillator
32.64Sell
Aroon Oscillator
22.00Sell
BOP
-0.33Sell
CCI
-8.88Neutral
Williams %R
-80.36Buy
Momentum
-10.70Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 6
Bearish signals: 3 out of 9 moving averages
EMA 9
1449.92Sell
SMA 9
1451.28Sell
EMA 21
1433.47Buy
SMA 21
1434.09Buy
EMA 50
1392.02Buy
SMA 50
1389.10Buy
EMA 200
1222.55Buy
SMA 200
1166.47Buy
WMA 20
1458.42Sell
Pivot
Pivot
Classic
Resistance 5
1557.83
Resistance 4
1531.63
Resistance 3
1505.43
Resistance 2
1479.23
Resistance 1
1464.57
Pivot
1453.03
Support 1
1438.37
Support 2
1426.83
Support 3
1400.63
Support 4
1374.43
Support 5
1348.23
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Alivus Life Sciences Share Price
1436.90+0.00 (-0.90%)
+58.98% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 74.85% | 74.87% | 74.87% | 74.91% | 74.91% | 74.94% |
| 5.93% | 5.54% | 5.30% | 5.08% | 6.84% | 6.42% |
| 1.74% | 1.53% | 1.64% | 1.69% | 1.60% | 1.56% |
| 5.29% | 5.65% | 5.63% | 5.44% | 3.87% | 4.06% |
| 12.19% | 12.41% | 12.56% | 12.88% | 12.78% | 13.02% |
Bulk & block deals
Name
Param Capital
Bandhan Mutual Fund
Nirma Limited
Nirma Limited
Norges Bank On Account Of The Government Pension Fund Global
Helios Mutual Fund
Helios Mutual Fund
Bandhan Mutual Fund
Param Capital
Bandhan Mutual Fund
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 06 Nov 2026 | Purchase | 99.97 Cr | ₹1,370 | 7.30 L | Bulk | 0.593433 | NSE |
| 06 Nov 2026 | Purchase | 117.27 Cr | ₹1,370 | 8.56 L | Bulk | 0.696096 | NSE |
| 06 Nov 2026 | Sell | 118.58 Cr | ₹1,422.29 | 8.34 L | Bulk | 0.677985 | NSE |
| 06 Nov 2026 | Sell | 389.94 Cr | ₹1,370 | 28.46 L | Bulk | 2.31468 | NSE |
| 06 Nov 2026 | Purchase | 25.07 Cr | ₹1,370 | 1.83 L | Block | 0.14882 | NSE |
| 06 Nov 2026 | Purchase | 15.89 Cr | ₹1,370 | 1.16 L | Block | 0.094334 | NSE |
| 06 Nov 2026 | Purchase | 13.91 Cr | ₹1,370 | 1.01 L | Block | 0.082542 | NSE |
| 06 Nov 2026 | Purchase | 82.20 Cr | ₹1,370 | 6 L | Block | 0.487935 | NSE |
| 06 Nov 2026 | Purchase | 99.97 Cr | ₹1,370 | 7.30 L | Block | 0.593433 | NSE |
| 06 Nov 2026 | Purchase | 27.40 Cr | ₹1,370 | 2 L | Block | 0.162645 | NSE |
Insider trading & SAST
Client name
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Limited
Glenn Mario Saldanha
Glenmark Pharmaceuticals Ltd
Nirma Ltd
Glenmark Pharmaceuticals Ltd
Nirma Ltd
Glenmark Pharmaceuticals Limited
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24 Dec 2024 | Promoter | Pledge | 20 | — | 0 | — | 2.45 Cr | 12 Mar 2024 | Release | 96,09,571 | SAST | Reg31 | — |
| 22 Jul 2024 | Promoter | Disposal | 7.84 | — | 0 | — | 96.10 L | 11 Jul 2024 - 12 Jul 2024 | Offer For Sale | — | SAST | 29(2) | — |
| 17 Jul 2024 | Promoter | Non disposal undertaking | — | — | 0 | — | 96.10 L | 04 Jul 2024 | Release | 0 | SAST | Reg31 | — |
| 15 Jul 2024 | Promoter | Disposal | 7.842806 | 0 | 798.30 Cr | ₹830.73 | 96.10 L | 11 Jul 2024 - 12 Jul 2024 | Others | 0 | Insider Trading | — | Equity Shares |
| 15 Jul 2024 | Promoter Group | Disposal | 0.006366 | 0 | 64.71 L | ₹829.63 | 7.80 K | 11 Jul 2024 - 12 Jul 2024 | Others | 0 | Insider Trading | — | Equity Shares |
| 19 Mar 2024 | Promoter | Disposal | 20 | 7.84 | 0 | — | 2.45 Cr | 12 Mar 2024 | Off Market | 96,09,571 | SAST | 29(2) | — |
| 19 Mar 2024 | Promoter | Acquisition | 20 | 75 | 0 | — | 2.45 Cr | 12 Mar 2024 | Off Market | 9,18,96,285 | SAST | 29(2) | — |
| 14 Mar 2024 | Promoter | Disposal | 55 | 27.84 | 0 | — | 6.74 Cr | 06 Mar 2024 | Off Market | 3,41,15,006 | SAST | 29(2) | — |
| 14 Mar 2024 | Promoter | Acquisition | 55 | 55 | 0 | — | 6.74 Cr | 05 Mar 2024 - 06 Mar 2024 | Off Market | 6,73,90,850 | SAST | 29(1) | — |
| 13 Mar 2024 | Promoter | Disposal | 19.999996 | 7.84 | 1,465.40 Cr | ₹597.99 | 2.45 Cr | 12 Mar 2024 | Off Market | 96,09,571 | Insider Trading | — | Equity Shares |
Alivus Life Sciences Share Price
1436.90+0.00 (-0.90%)
+58.98% past 1 Year
Glenmark Life Sciences Limited is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system
Corporate Actions
Date
Type
Details
Company details
Alivus Life Sciences Share Price
1436.90+0.00 (-0.90%)
+58.98% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Alivus Life Sciences Share Price
1436.90+0.00 (-0.90%)
+58.98% past 1 Year
News
1 of 20
Stock NewsALIVUS11 Nov 2026
Alivus Life Sciences has entered into an agreement to acquire a 76% stake in IQGen-X Pharma Private Limited for approximately Rs 9.12 crores in cash, subject to customary adjustments and fulfilment of conditions precedent. The transaction covers 8,60,589 equity shares, each with a face value of Rs 10, in the target company.
IQGen-X Pharma reported revenue of approximately Rs 3.48 crores for the year ended March 31, 2026. The acquisition is expected to close by the end of the current calendar year. If the conditions precedent are not fulfilled within the agreed timeline, the sellers are required to enter into a Business Transfer Agreement with Alivus covering IQGen-X Pharma's business, employees and assets.
The transaction gives Alivus a controlling interest in IQGen-X Pharma and may broaden its pharmaceutical business and market presence. The available information does not specify an immediate stock price reaction, earnings contribution, leverage impact or additional financial guidance.
Alivus Life Sciences’ promoter sells 2.31% stake for Rs 390 crore
Stock NewsALIVUS9 Nov 2026
Nirma has offloaded around 28.46 lakh shares of the company at an average price of Rs 1,370.00 apiece
Alivus Reports Strong Q2 EBITDA Growth And Margin Expansion
ResultALIVUS29 Oct 2026
Alivus reported Q2 EBITDA of Rs 265 crores, rising from Rs 180 crores year on year, implying 47.2 percent growth. EBITDA margin expanded to 38.88 percent from 30.46 percent in the corresponding year-ago quarter, an improvement of 842 basis points. Revenue and PAT figures, sequential performance, street expectations, and market reaction were not provided in the available information. The result indicates stronger operating profitability and improved margin performance for the quarter.
Alivus Q2 Net Profit Rises 51.5 Percent With Stronger Revenue And Margins
ResultALIVUS29 Oct 2026
Alivus Life Sciences reported Q2 consolidated revenue of Rs 682 crores, up 16 percent year on year and 6.5 percent quarter on quarter. EBITDA increased 48 percent year on year to Rs 265 crores from Rs 179 crores, while EBITDA margin expanded to 38.9 percent from 30.5 percent. Net profit rose 51.5 percent year on year to Rs 197 crores from Rs 130 crores and increased 22.9 percent sequentially from Rs 160 crores. The results reflected stronger operating performance, supported by growth in non-GPL active pharmaceutical ingredients and contract development and manufacturing operations. No street expectations or market reaction were provided.
Alivus Q2 Revenue Rises 16 Percent Year on Year to Rs 682 Crores
ResultALIVUS29 Oct 2026
Alivus Life Sciences reported Q2 revenue of Rs 682 crores, compared with Rs 590 crores in the corresponding quarter a year earlier, representing 16 percent year on year growth. The company name, NSE symbol ALIVUS, and ISIN INE03Q201024 are confirmed through NSE records. EBITDA, PAT, operating margin, net margin, sequential revenue change, street expectations, management commentary, and market reaction were not provided in the available update.
Alivus Life Sciences Acquires Stake In Torrent Urja For Renewable Energy Compliance
Stock NewsALIVUS7 Oct 2026
Alivus Life Sciences has acquired a 9.21 percent stake in Torrent Urja 19 Private Limited for Rs 14.04 crores. The investment is intended to strengthen the company’s renewable energy focus and support compliance with applicable Electricity Act standards. The transaction represents a strategic investment outside Alivus Life Sciences’ core pharmaceutical operations and may help secure access to renewable power or related electricity arrangements. The immediate effect on revenue, earnings, leverage, and market share is not specified in the available information. No stock price reaction has been provided.
Alivus Life Sciences to acquire 76 percent stake in Iqgen-X Pharma
Stock NewsALIVUS18 Aug 2026
Alivus Life Sciences has announced that its board has approved the purchase of a 76 percent stake in Iqgen-X Pharma for a total consideration of Rs 9.12 crores. The proposed transaction represents a controlling interest in Iqgen-X Pharma, indicating a strategic move by Alivus Life Sciences to expand its presence within the pharmaceuticals and life sciences space. By securing a majority stake, the company is positioned to integrate Iqgen-X Pharma’s operations, portfolio, or capabilities into its existing business, which could enhance its product pipeline, strengthen its research and development base, or widen its market reach in both domestic and export segments, depending on Iqgen-X Pharma’s current business profile.
The deal size of Rs 9.12 crores suggests a relatively modest acquisition by listed market standards, pointing to a focused, possibly niche addition rather than a transformational transaction for Alivus Life Sciences. Nonetheless, owning 76 percent provides effective control over key strategic and operational decisions at Iqgen-X Pharma, which may support future consolidation, scaling up of production, or entry into new therapeutic or geographic markets. The acquisition may also have implications for Alivus Life Sciences’ earnings trajectory over the medium term if synergies in manufacturing, distribution, or intellectual property are realised. While detailed financial metrics for Iqgen-X Pharma and any funding structure for the purchase consideration are not disclosed in the available context, investors and market participants are likely to monitor subsequent disclosures from the company and any regulatory filings for clarity on earnings accretion, integration plans, and potential impact on leverage or cash flows. In the near term, this development is expected to be viewed as a strategic corporate action, though not of an index-moving scale.
Alivus Life Sciences Q1 EBITDA grows with strong margin expansion YoY
ResultALIVUS30 Jul 2026
Alivus Life Sciences has reported a notable improvement in its operating performance for the latest reported first quarter. The company’s Q1 EBITDA stood at Rs 210.00 crores, compared to Rs 170.00 crores in the corresponding quarter of the previous year, indicating a healthy year-on-year increase in operating earnings. This growth in EBITDA suggests better operating leverage and potentially improved cost efficiencies or a more favourable product mix within its life sciences portfolio.
Alongside the rise in absolute EBITDA, Alivus Life Sciences has also delivered meaningful margin expansion. The Q1 EBITDA margin improved to 33.06% from 28.64% on a year-on-year basis, reflecting a substantial enhancement in profitability at the operating level. Such margin improvement typically points to disciplined cost management, benefits from scale, or a shift towards higher-margin offerings. While detailed revenue, PAT, and quarter-on-quarter comparisons are not available in the provided context, the combination of higher EBITDA and stronger margins indicates an overall strengthening of the company’s core operations during the quarter.
No information is available in the context on revenue trends, net profit figures, management commentary, guidance, or how the reported numbers compare with street expectations. Similarly, there is no data on stock price reaction, F&O positioning, or broader sector-specific developments directly linked to Alivus Life Sciences. Within these constraints, the key takeaway from the reported numbers is the clear year-on-year improvement in operating profitability, both in absolute EBITDA and in margin profile, which is an important indicator for investors tracking the company’s financial trajectory.
Alivus Life Sciences reports strong Q1 revenue growth of 6.7 percent YoY
ResultALIVUS30 Jul 2026
Alivus Life Sciences has reported a year-on-year improvement in its financial performance for the latest reported quarter, with Q1 revenue coming in at Rs 640.00 crores compared to Rs 600.00 crores in the corresponding period last year. This represents an approximate 6.7 percent growth in top-line on a YoY basis, indicating healthy demand traction and an expansion in the company’s revenue base. The reported numbers suggest that the company has been able to scale its operations and maintain or improve its market positioning within the life sciences and pharmaceutical value chain, although detailed segmental contributions are not available in the provided context.
Key profitability metrics such as EBITDA, PAT, and associated margin trends are not disclosed in the given information, and therefore cannot be assessed or interpreted. Similarly, there is no data on quarter-on-quarter comparisons, operating or net margin movements, or management commentary related to costs, pricing, or pipeline developments. Street expectations, consensus forecasts, and any deviation from those benchmarks have also not been mentioned, preventing a calibrated view on whether the revenue performance is considered a beat, miss, or in-line relative to market expectations. In the absence of verifiable information on stock price reaction, trading volumes, or F&O activity around the announcement, the immediate market response and potential short-term impact on the share price cannot be inferred.
Based solely on the available numbers, the primary takeaway is that Alivus Life Sciences has delivered a solid year-on-year increase in revenue in Q1, which is typically viewed as operationally positive. However, a fuller assessment of financial health, profitability quality, and sustainability of growth would require additional, verifiable disclosures on margins, earnings, cash flows, and any strategic guidance provided by the management.
Alivus Life Sciences Q1 net profit rises 33 percent year-on-year
ResultALIVUS30 Jul 2026
Alivus Life Sciences has reported a strong improvement in profitability for the first quarter, with standalone net profit rising to Rs 160.00 crores from Rs 120.00 crores in the corresponding quarter of the previous financial year. This represents an increase of roughly 33 percent year-on-year in bottom-line performance. The higher profit suggests better operating performance, improved cost efficiency, or a more favourable product mix in the company’s life sciences and pharmaceuticals-related businesses, though detailed drivers are not disclosed in the available update. Revenue, EBITDA, and margin data are not provided, so the exact evolution of operating and net profit margins cannot be quantified. However, a 33 percent expansion in net profit on a year-on-year basis typically indicates either robust top-line growth, margin expansion, or a combination of both, especially in a sector where scale and product differentiation play an important role.
Street expectations, management commentary, and specific guidance for the remainder of the financial year are not available in the given context, and there is no reference to how the share price reacted post result announcement. As a result, it is not possible to verify whether the performance was ahead of, in line with, or below consensus estimates. Similarly, quarter-on-quarter comparisons, detailed segmental performance, R&D spending trends, and any changes in leverage or cash generation are not captured in the current information set and are therefore not discussed. Based solely on the disclosed numbers, the key takeaway is that Alivus Life Sciences has delivered a materially higher standalone net profit in Q1 in absolute terms versus the same quarter last year, indicating an improved earnings trajectory at the company level.
Alivus Life Sciences to host Q1 FY27 earnings conference call on July 31
Stock NewsALIVUS23 Jul 2026
Alivus Life Sciences has scheduled its Q1 earnings conference call for July 31, with the call to commence at 8:30 am. The announcement indicates that the company is preparing to discuss its financial and operational performance for the first quarter of the current financial year with investors, analysts, and other market participants. Earnings calls typically cover key metrics such as revenue trends, margins, profitability, and guidance, along with management commentary on business strategy, regulatory environment, and industry dynamics. For Alivus Life Sciences, the upcoming call will be an important event for stakeholders to gauge the momentum in its core operations, understand any changes in cost structures, and assess the impact of recent business initiatives on growth and earnings visibility.
The timing of the call at 8:30 am suggests that management aims to provide adequate time for participants to review and interpret the numbers and commentary ahead of regular market hours or early in the trading session, depending on the exchange schedule. While specific financial details such as revenue, EBITDA, net profit, or margin performance for the quarter have not yet been disclosed in the available context, the formal scheduling of a Q1 earnings call underscores the company’s intent to maintain transparency and regular communication with the market. Participants will likely focus on management’s outlook for subsequent quarters, any commentary on regulatory developments affecting the life sciences sector, and potential implications for the company’s leverage, capital allocation, and long-term growth strategy. In the absence of quantified results or guidance in the current disclosure, market reaction will depend on the actual numbers and qualitative commentary shared during the call.
Alivus Life Sciences Reports Q4 EBITDA Growth to Rs 210 Crores, Margin Expands to 31.13%
ResultALIVUS14 May 2026
Alivus Life Sciences announced its Q4 financial results, posting EBITDA of Rs 210.00 crores, marking an improvement from Rs 198.00 crores in the year-ago quarter. This represents a YoY growth in absolute EBITDA terms.
The EBITDA margin expanded to 31.13% from 30.56% YoY, indicating enhanced operational efficiency. No details on revenue, PAT, or QoQ comparisons were provided in the update. Street expectations or management guidance were not mentioned.
These results highlight positive momentum in the life sciences sector player amid its earnings season disclosures.
Alivus Life Sciences Reports Strong Q4FY25 Earnings with Profit and Revenue Growth
ResultALIVUS14 May 2026
Alivus Life Sciences announced its Q4 financial results, registering a sequential net profit increase to Rs 162.00 crores from Rs 140.00 crores in the previous year (YoY growth). The company also reported revenue growth to Rs 690.00 crores compared to Rs 650.00 crores YoY, reflecting improved top-line performance.
Key financial highlights include robust year-over-year expansion in both revenue and net profit metrics, underscoring operational strength in the life sciences sector. No details on EBITDA, margins, or comparisons to street expectations were provided in the announcement.
Alivus Life Sciences reports Profit after tax of 162.66 Crores, in the March 2026 quarter
ResultALIVUS14 May 2026
NULL
Alivus Life Sciences informs about disclosure
Stock NewsALIVUS21 Mar 2026
NULL
Alivus Life Sciences Fire Incident At Dahej: Production Recovery Timeline Announced
Stock NewsALIVUS25 Feb 2026
Alivus Life Sciences reported a fire incident at its Dahej manufacturing facility in Gujarat on February 14, 2026, at approximately 23:00 hrs. The fire was confined to a single production block out of seven, with the Active Pharmaceutical Ingredient (API) manufacturing units within that block remaining entirely unaffected. Three personnel sustained injuries during the incident, and the situation was brought under control within one hour. All six other production blocks at the Dahej facility remain fully operational.
The company has finalized its damage assessment and established clear recovery timelines. API production at the affected block is scheduled to resume on March 1, 2026, while intermediate production is expected to recommence in mid-March 2026. Management has acknowledged that this temporary cessation will result in minor shipment delays. The company has confirmed adequate insurance coverage and is in the process of intimating insurance companies regarding the incident.
The Dahej facility is a key manufacturing site for Alivus Life Sciences. While the immediate operational impact is contained to intermediate production capabilities, the temporary halt poses risks to revenue streams, supply chain commitments, and working capital if inventory buffers prove insufficient. The company remains committed to stringent safety standards and implementing precautionary measures to prevent recurrence. Investors are likely to monitor further updates on the quantum of financial loss, insurance claim outcomes, and adherence to the stated production recovery timeline.
The company has finalized its damage assessment and established clear recovery timelines. API production at the affected block is scheduled to resume on March 1, 2026, while intermediate production is expected to recommence in mid-March 2026. Management has acknowledged that this temporary cessation will result in minor shipment delays. The company has confirmed adequate insurance coverage and is in the process of intimating insurance companies regarding the incident.
The Dahej facility is a key manufacturing site for Alivus Life Sciences. While the immediate operational impact is contained to intermediate production capabilities, the temporary halt poses risks to revenue streams, supply chain commitments, and working capital if inventory buffers prove insufficient. The company remains committed to stringent safety standards and implementing precautionary measures to prevent recurrence. Investors are likely to monitor further updates on the quantum of financial loss, insurance claim outcomes, and adherence to the stated production recovery timeline.
Alivus Life Sciences informs about updates
Stock NewsALIVUS16 Feb 2026
NULL
Fire at Alivus Life Sciences API Plant in Dahej Injures Three; Company Assessing Damages.
Stock NewsALIVUS16 Feb 2026
A fire erupted at Alivus Life Sciences' API manufacturing plant in Dahej, Gujarat, on February 14, 2026, at around 23:00 Hrs, resulting in three people injured. The company is investigating the cause of the incident and evaluating the extent of damages. Alivus Life Sciences has confirmed sufficient insurance coverage is secured to mitigate potential financial impact.
The Dahej facility is a key production site for the company's Active Pharmaceutical Ingredients (APIs), with recent expansions including additional 240 KL capacity in 2023 and completion of a brownfield oncology plant project. This event may disrupt API production and supply chain, potentially affecting earnings in the near term, though insurance coverage could limit net financial loss. No specific quantum of damages or production downtime has been disclosed yet.
Alivus Life Sciences Management Guides for Additional CDMO Projects by Q1 FY27, Double-Digit Growth from FY28-29.
Stock NewsALIVUS23 Jan 2026
Alivus Life Sciences management, in a recent concall update, anticipates concluding one or two additional CDMO projects by Q1 FY27. The company expects to achieve double-digit growth starting from FY28-29. This guidance underscores the company's focus on expanding its CDMO segment, which has shown robust historical performance, including 91% YoY growth in Q1 FY24.
Alivus Life Sciences operates in the generic API and CDMO spaces, with CDMO involving contract development and manufacturing for multinational and specialty pharmaceutical companies. Past updates highlight ongoing discussions for new business opportunities and capacity expansions, such as brownfield projects in Dahej and new modules in Ankleshwar, alongside strategic ramps in complex API platforms including iron compounds and oncology.
These developments may enhance revenue streams and market share in regulated markets like US and Europe, where CDMO contributes significantly. The guidance signals potential for sustained earnings growth through diversified project pipeline and operational efficiencies.
Alivus Life Sciences Solapur Plant Operations Timeline and Capacity Utilization Guidance
Stock NewsALIVUS23 Jan 2026
Alivus Life Sciences has provided operational guidance regarding its greenfield Solapur plant, a cornerstone of its capacity expansion strategy. The facility is expected to commence operations by July 2026, with Phase 1 construction (200 KL capacity) currently underway. Upon coming online, the new capacity is projected to achieve 85-90% capacity utilization, indicating strong demand expectations and operational readiness. This timeline aligns with management's previously stated target of April 2026 operational commencement, with the July guidance likely reflecting a conservative revision or phased ramp-up approach.
The Solapur expansion is part of Alivus's multi-facility capex program. Concurrently, brownfield expansions at Ankleshwar (100 KL addition, expected operational by Q2 FY27) and Dahej (160 KL addition, expected operational by Q1 FY27) are progressing on schedule. The company allocated Rs 113 crore capex in H1 FY26 against a Rs 600 crore annual budget, with management expecting approximately Rs 250 crore spending in H2, emphasizing deliberate execution for FDA approvability.
The high projected capacity utilization (85-90%) reflects strong underlying demand for Alivus's high-value API portfolio and CDMO services across regulated markets including North America, Europe, Japan, and LATAM. This operational efficiency supports management's FY26 guidance of high single-digit revenue growth and sustained EBITDA margins around 30%. The company maintains a robust financial position with Rs 653 crore in cash and equivalents (debt-free), providing ample liquidity for ongoing capex commitments.
The Solapur expansion is part of Alivus's multi-facility capex program. Concurrently, brownfield expansions at Ankleshwar (100 KL addition, expected operational by Q2 FY27) and Dahej (160 KL addition, expected operational by Q1 FY27) are progressing on schedule. The company allocated Rs 113 crore capex in H1 FY26 against a Rs 600 crore annual budget, with management expecting approximately Rs 250 crore spending in H2, emphasizing deliberate execution for FDA approvability.
The high projected capacity utilization (85-90%) reflects strong underlying demand for Alivus's high-value API portfolio and CDMO services across regulated markets including North America, Europe, Japan, and LATAM. This operational efficiency supports management's FY26 guidance of high single-digit revenue growth and sustained EBITDA margins around 30%. The company maintains a robust financial position with Rs 653 crore in cash and equivalents (debt-free), providing ample liquidity for ongoing capex commitments.

